Roivant Sciences reported that its inhaled mosliciguat met primary and key secondary endpoints in a 16-week Phase 2 study for pulmonary hypertension, including a 56% placebo-adjusted reduction in pulmonary vascular resistance. The company also posted significant improvements in exercise capacity and heart-failure biomarkers, strengthening the case for a new therapeutic approach. According to the company, mosliciguat delivered a 35-meter placebo-adjusted improvement in six-minute walk distance and reduced NT-proBNP by 53% versus placebo—results that Roivant framed as consistent with clinically meaningful cardiopulmonary benefit. The readout is particularly relevant as the asset traces back to Bayer acquisition efforts, adding context to how Roivant is monetizing mid-stage opportunities. The Phase 2 outcome is expected to influence near-term discussions with investors and partners around next-step trial design and timing, especially as the company positions its pipeline toward potential registrational paths.